Brief: ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions
05/03/2025 22:09
March 5 (Reuters) - ARS Pharmaceuticals Inc SPRY.O: ARS PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEFFY® 1 MG (EPINEPHRINE NASAL SPRAY) FOR TYPE I ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, IN PEDIATRIC PATIENTS WEIGHING 15 TO < 30 KILOGRAMS ARS PHARMACEUTICALS INC - NEFFY 1 MG IS EXPECTED TO BE AVAILABLE IN U.S. BY END OF MAY 2025 ARS PHARMACEUTICALS: MOST COMMERCIALLY INSURED PATIENTS WILL PAY NO MORE THAN $25 FOR TWO SINGLE-USE NEFFY DEVICES THROUGH A CO-PAY SAVINGS PROGRAM ARS PHARMACEUTICALS INC: IF PRODUCT ISN'T COVERED BY INSURANCE, CASH PRICE OF $199 FOR TWO DOSES IS AVAILABLE THROUGH BLINKRX Source text: ID:nGNX3b0hhs Further company coverage: SPRY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle